Other languages Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
10.19 ^USD	-4.05%		-1.26%	-9.02%

Apr. 11	Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	MT
Mar. 22	B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	Mar. 20
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Restore stock falls as weak tech trading drags down annual results	Mar. 14
Harrow, Inc. Announces Board of Director Appointments	Jan. 29
Harrow Health's Eye Treatment Drug Vevye Now Available in US	Jan. 11
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	Jan. 03
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	Jan. 03
Harrow, Inc. Appoints John P. Saharek as President and Chief Executive Officer of its ImprimisRx Division	Jan. 03
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application	Nov. 29
Top Premarket Decliners	Nov. 14
Harrow Health Q3 Core Loss Widens, Revenue Rises; Shares Plunge After Hours	Nov. 13
Harrow, Inc. Revises Revenue Guidance for the Full Year 2023	Nov. 13
Harrow, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024	Nov. 13
Harrow, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Harrow, Inc. Announces Board and Committee Changes	Nov. 03
Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S	23-10-24
Insider Buy: Harrow Health	23-08-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Harrow, Inc.

Equities

HROW

US4158581094

Other languages

Filters